Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Navigating liver cancer: Precision targeting for enhanced treatment outcomes.Drug delivery and translational research · 2025
   Review
2. The New Updated Barcelona Clinic Liver Cancer Staging System: Roles of Trans-arterial Chemoembolization and Homework to Interventional Radiologists.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025
   Review
3. Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule.Journal of liver cancer · 2023
   Article
4. New concepts in the treatment of hepatocellular carcinoma.United European gastroenterology journal · 2022
   Review
5. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.Journal of hepatology · 2022
   Review
6. TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p.Journal of Cancer · 2022
   Article
7. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models.Journal of hepatocellular carcinoma · 2021
   Article
8. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience.Updates in surgery · 2020
   Article
9. Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Liver cancer · 2020
   Article
10. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.Gut and liver · 2018
    Article
11. Controversies and evidence of hepatic resection for hepatocellular carcinoma.BBA clinical · 2016
    Review
12. Up-regulated expression of phospholipase C, β1 is associated with tumor cell proliferation and poor prognosis in hepatocellular carcinoma.OncoTargets and therapy · 2016
    Article
13. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study.Medicine · 2016
    Article
14. Intermediate-stage HCC--upfront resection can be feasible.Nature reviews. Clinical oncology · 2015
    Article

Corrections and comments

• Comment on
  Treatment of intermediate-stage hepatocellular carcinoma.2014
• Comment on
  Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.2015

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as